| Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance SY Ku, S Rosario, Y Wang, P Mu, M Seshadri, ZW Goodrich, ... Science 355 (6320), 78-83, 2017 | 900 | 2017 |
| SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ... Science 355 (6320), 84-88, 2017 | 883 | 2017 |
| Epigenetics in cancer: targeting chromatin modifications L Ellis, PW Atadja, RW Johnstone Molecular cancer therapeutics 8 (6), 1409-1420, 2009 | 619 | 2009 |
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma L Ellis, Y Pan, GK Smyth, DJ George, C McCormack, R Williams-Truax, ... Clinical Cancer Research 14 (14), 4500-4510, 2008 | 346 | 2008 |
| Targeting tumor angiogenesis with histone deacetylase inhibitors L Ellis, H Hammers, R Pili Cancer letters 280 (2), 145-153, 2009 | 292 | 2009 |
| Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma RK Lindemann, A Newbold, KF Whitecross, LA Cluse, AJ Frew, L Ellis, ... Proceedings of the National Academy of Sciences 104 (19), 8071-8076, 2007 | 250 | 2007 |
| Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer G Zadra, CF Ribeiro, P Chetta, Y Ho, S Cacciatore, X Gao, S Syamala, ... Proceedings of the National Academy of Sciences 116 (2), 631-640, 2019 | 231 | 2019 |
| Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models L Shen, M Ciesielski, S Ramakrishnan, KM Miles, L Ellis, P Sotomayor, ... PloS one 7 (1), e30815, 2012 | 218 | 2012 |
| Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study HJ Hammers, HM Verheul, B Salumbides, R Sharma, M Rudek, J Jaspers, ... Molecular cancer therapeutics 9 (6), 1525-1535, 2010 | 190 | 2010 |
| ONECUT2 is a driver of neuroendocrine prostate cancer H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ... Nature communications 10 (1), 278, 2019 | 189 | 2019 |
| Prostate cancer reactivates developmental epigenomic programs during metastatic progression MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ... Nature genetics 52 (8), 790-799, 2020 | 184 | 2020 |
| High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program DP Labbé, G Zadra, M Yang, JM Reyes, CY Lin, S Cacciatore, EM Ebot, ... Nature communications 10 (1), 4358, 2019 | 143 | 2019 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy L Ellis, M Bots, RK Lindemann, JE Bolden, A Newbold, LA Cluse, CL Scott, ... Blood, The Journal of the American Society of Hematology 114 (2), 380-393, 2009 | 132 | 2009 |
| TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup DP Labbé, CJ Sweeney, M Brown, P Galbo, S Rosario, KM Wadosky, ... Clinical Cancer Research 23 (22), 7072-7083, 2017 | 112 | 2017 |
| Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models L Shen, A Sundstedt, M Ciesielski, KM Miles, M Celander, R Adelaiye, ... Cancer immunology research 3 (2), 136-148, 2015 | 101 | 2015 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 98 | 2021 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature communications 12 (1), 1979, 2021 | 88 | 2021 |
| Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer L Ellis, SY Ku, S Ramakrishnan, E Lasorsa, G Azabdaftari, A Godoy, R Pili Oncotarget 4 (12), 2225, 2013 | 87 | 2013 |
| Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells R Minelli, R Cavalli, L Ellis, P Pettazzoni, F Trotta, E Ciamporcero, ... European journal of pharmaceutical sciences 47 (4), 686-694, 2012 | 87 | 2012 |
Sheng-Yu KuDana-Farber Cancer InstituteVerified email at dfci.harvard.edu
